Recidiva y factores pronósticos tras tratamiento con antitiroideos en la enfermedad de Graves-Basedow. Estudio multicéntrico en el norte de España

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Revista Clinica Espanola

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1016/S0014-2565(00)70566-2
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prediction of the course of Graves' disease after medical antithyroid treatment.

  2009cited by this paper
• Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long‐term prospective study

  1998cited by this paper
• Evolución de los criterios diagnósticos y terapéuticos en la enfermedad de Graves en España. Comparación de los resultados de dos encuestas realizadas en 1987 y 1995

  1998cited by this paper
• A randomized trial of short‐term treatment of Graves' disease with high‐dose carbimazole plus thyroxine versus low‐dose carbimazole

  1998cited by this paper
• The Prognostic Value of Thyrotropin Receptor Antibody Measurement in the Early Stages of Treatment of Graves' Disease with Antithyroid Drugs

  1998cited by this paper
• Clinical Features of Patients with Graves' Disease Undergoing Remission After Antithyroid Drug Treatment

  1997cited by this paper
• Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug.

  1996cited by this paper
• Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease.

  1994cited by this paper
• Age‐Related Therapeutic Response to Antithyroid Drug in Patients with Hyperthyroid Graves' Disease

  1994cited by this paper
• A prospective randomized trial of antithyroid drug dose in Graves' disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment.

  1993cited by this paper
• Antithyroid drug and Graves’ hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission

  1992cited by this paper
• [Synthetic antithyroid drugs and Basedow's disease or the choice of a therapeutic strategy].

  1991cited by this paper
• Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.

  1991cited by this paper
• Differences and Similarities in the Diagnosis and Treatment of Graves' Disease in Europe, Japan, and The United States

  1991cited by this paper
• Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.

  1990cited by this paper
• Factors influencing the outcome of thyrostatic drug therapy in Graves' disease.

  1990cited by this paper
• The Prognostic Value of Thyrotropin Receptor Antibody (TRAb) Levels in Graves' Disease

  1990cited by this paper
• Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration.

  1990cited by this paper
• Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease.

  1989cited by this paper
• ANTITHYROID DRUGS IN THE TREATMENT OF HYPERTHYROIDISM OF Graves' DISEASE: LONG‐TERM FOLLOW‐UP OF 434 PATIENTS

  1989cited by this paper
• Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.

  1988cited by this paper
• Prevalence, concentration, and prognostic importance of proteinuria in patients with malignancies

  1988cited by this paper
• Prediction of remission after antithyroid drug treatment in Graves' disease.

  1988cited by this paper
• Do HLA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves' thyrotoxicosis after antithyroid drug treatment?

  1987cited by this paper
• Remission rates with antithyroid drug therapy: continuing influence of iodine intake?

  1987cited by this paper
• The management of hyperthyroidism due to Graves' disease in Europe in 1986. Results of an international survey.

  1987cited by this paper
• Retrospective revaluation of the significance of thyroid microsomal antibody in the treatment of Graves' disease

  1987cited by this paper
• Prediction of outcome in Graves' disease after carbimazole treatment.

  1986cited by this paper
• THE ABILITY OF THE SERUM THYROTROPHIN RECEPTOR ANTIBODY (TRAb) INDEX AND HLA STATUS TO PREDICT LONG‐TERM REMISSION OF THYROTOXICOSIS FOLLOWING MEDICAL THERAPY FOR GRAVEs' DISEASE

  1986cited by this paper
• Goitre size and outcome of medical treatment of Graves' disease.

  1986cited by this paper
• Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves' disease as an indicator of remission.

  1985cited by this paper
• THYROID STIMULATING ANTIBODIES: AN AID TO THE STRATEGY OF TREATMENT OF GRAVES' DISEASE?

  1984cited by this paper
• Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism.

  1983cited by this paper
• A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.

  1983cited by this paper
• Syndrome of persisting thyroid stimulating immunoglobulins and growth promotion of goiter combined with low thyroxine and high triiodothyronine serum levels in drug treated Graves’ disease

  1983cited by this paper
• Follow-up comparison of short-term versus 1-year antithyroid drug therapy for the thyrotoxicosis of Graves' disease.

  1982cited by this paper
• Prognostic value of thyrotrophin binding inhibiting immunoglobulins (TBII) in longterm antithyroid treatment, 131I therapy given in combination with carbimazole and in euthyroid ophthalmopathy.

  1981cited by this paper
• Changes in thyroid-stimulating antibody activity in Graves' disease treated with antithyroid drug and its relationship to relapse: a prospective study.

  1980cited by this paper
• Clinical significance of assay of thyroid-stimulating antibody in Graves' disease.

  1980cited by this paper
• THYROTROPHIN BINDING INHIBITING IMMUNOGLOBULINS IN GRAVES' DISEASE BEFORE, DURING AND AFTER ANTITHYROID THERAPY, AND ITS RELATION TO LONG‐ACTING THYROID STIMULATOR

  1980cited by this paper
• Thionamide therapy in Graves' disease: relation of relapse rate to duration of therapy.

  1980cited by this paper
• Prediction of relapse in hyperthyroid Graves' disease.

  1980cited by this paper
• Human thyroid stimulating activity and clinical state in antithyroid treatment of juvenile Graves' disease.

  1980cited by this paper
• THE SPECTRUM OF THYROID DISEASE IN A COMMUNITY: THE WHICKHAM SURVEY

  1977cited by this paper
• Low remission after therapy for Graves disease. Possible relation of dietary iodine with antithyroid therapy results.

  1973cited by this paper

• Evaluation of YouTube As A Source For Graves' Disease Information: Is High‐Quality Guideline‐Based Information Available?

  2024cites this paper
• A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves’ Hyperthyroidism?

  2020cites this paper
• Citopatología y bioquímica del líquido pleural reumatoideo. A propósito de un caso

  2019cites this paper
• Comparison of the long-term efficacy of low dose 131I versus antithyroid drugs in the treatment of hyperthyroidism

  2009cites this paper
• Traitement de la maladie de Basedow : 300 cas

  2004cites this paper
• De tuberculosis a aspergiloma pulmonar: A propósito de un caso

  2004cites this paper
• Evolución clínica de una cohorte de pacientes con enfermedad de Graves-Basedow tratados con metimazol

  2002cites this paper
• Factores pronósticos de recidiva en el tratamiento farmacológico de la enfermedad de Graves Basedow

  2002cites this paper
• Plasma and peripheral leukocyte beta-N-acetylhexosaminidase isoenzymes and disease activity in rheumatoid arthritis.

  2002cites this paper